share_log

东曜药业-B公布2023年实现营收7.81亿元 同比增长77%

Dongyao Pharmaceutical-B announced that it will achieve revenue of 781 million yuan in 2023, a 77% year-on-year increase

新浪港股 ·  Mar 17 21:10

Dongyao Pharmaceutical-B (01875) announced its 2023 results. The group's revenue was approximately RMB 781 million, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630 million, an increase of 107% over the previous year. The main contribution came from a sharp increase in sales performance of the core product, Park Hsin Ting (bevacizumab injection). CDMO/CMO business revenue was RMB 141 million, up 94% year over year. Excluding this factor, there was no one-time authorization income for the full year of 2023 (RMB 54,151 million for the full year of 2022). Excluding this factor, revenue for the full year of 2023 increased by 101% year-on-year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment